The ESMO presentation in October is the next major catalyst. Traders should watch for abstract release and any pre-ESMO data leaks. The stand-alone therapy data is particularly important as it could de-risk the asset from combination dependency and open a larger addressable market.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 17 $3.08entry
- T+1 · 4mo ago −4.39%α −4.23% · $2.94
- T+5 · 4mo ago −0.81%α −0.13% · $3.05
- T+20 · 3mo ago +8.62%α +4.17% · $3.34
- T+60 · 5w ago −2.44%α −7.12% · $3.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced it will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ESMO Congress in October 2026. The data from a phase 2 trial extension will show EVX-01's effect as a stand-alone therapy in advanced melanoma patients, building on previously reported two-year results showing a 75% objective response rate and durable responses. The presentation is a key catalyst for the stock, as positive data could support partnership discussions and late-stage development plans for this lead asset.
Key Facts
- Evaxion will present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 (October 23-27, 2026) in Madrid.
- The data comes from a one-year extension of the phase 2 trial where patients received EVX-01 as stand-alone therapy (without anti-PD-1 combination).
- Previously reported two-year data showed a 75% Objective Response Rate (ORR) with 12 of 16 patients responding, including 4 complete responses, and 92% of patients still responding at two years with no relapses.
- EVX-01 induced an immune response in all patients, with 86% of targeted neoantigens generating potent T-cell responses.
- The global market for melanoma treatments is estimated to grow to $7.4 billion by 2029.
Financial Impact
No financial figures provided; the event is a clinical data presentation at a major medical congress, which could materially impact partnership and valuation prospects for the lead asset EVX-01.
Risk Factors
- The phase 2 trial has only 16 patients, small sample size limits statistical significance and replicability.
- The company is pre-revenue and needs additional capital, as noted in forward-looking statement risk factors.
- Data is not yet released; the presentation is three months away, leaving room for negative pre-event drift or disappointing results.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004747 |
| Document: f6k_071726.htm | 0001171843-26-004747 |
| Document: 0001171843-26-004747-index-headers.html | 0001171843-26-004747 |
| Document: 0001171843-26-004747-index.html | 0001171843-26-004747 |
| Document: 0001171843-26-004747.txt | 0001171843-26-004747 |
Track record
50 reports on EVAX
7 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers